Physician profile
Ashley Oldham
NPI 1669858429
$1,042.23
in general payments reported to CMS, 2019-2025
25 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $405 · 2022: $90.44 · 2023: $142 · 2024: $17.49 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $498 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $497.95 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $111.46 | 2021-2023 | Trelegy Ellipta |
| Pfizer INC. | $84.40 | 2021-2025 | |
| Amarin Pharma, INC. | $82.88 | 2021-2022 | |
| Abbvie INC. | $69.34 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.95 | 2023-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.78 | 2021 | |
| Lilly USA, LLC | $59.64 | 2021-2025 | Zepbound |
| Otsuka America Pharmaceutical, INC. | $58.54 | 2022-2025 | Rexulti |
| Novo Nordisk INC | $45.78 | 2022-2025 | Ozempic, Wegovy |
| Vertex Pharmaceuticals Incorporated | $42.10 | 2025 | |
| Grifols USA, LLC | $41.55 | 2023 | Prolastin-C Liquid |
| Amgen INC. | $38.36 | 2021 | |
| Janssen Pharmaceuticals, INC | $32.14 | 2021 | |
| Organon LLC | $31.53 | 2021-2022 | |
| Astellas Pharma US INC | $25.57 | 2025 | Veozah |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $23.47 | 2021-2022 | |
| Antares Pharma, INC. | $22.29 | 2025 | Xyosted |
| Alkermes, INC. | $20.94 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.45 | 2023 | |
| Alexion Pharmaceuticals, INC. | $19.38 | 2025 | Strensiq |
| Novartis Pharmaceuticals Corporation | $17.49 | 2024 | |
| Axsome Therapeutics, INC. | $17.19 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $15.90 | 2025 | Voquezna |
| Verona Pharma, INC. | $15.64 | 2025 | Ohtuvayre |
| Esperion Therapeutics, INC. | $15.46 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Oldham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.